Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Compressive Dressing and Pharyngocutaneous Fistula After Primary Total Laryngectomy (TIGHT)

15 novembre 2026 mis à jour par: Andrea Galli, IRCCS San Raffaele

Impact of Compressive Dressing on the Risk of Pharyngocutaneous Fistula After Primary Total Laryngectomy: A Multicenter Retrospective Observational Study

Pharyngocutaneous fistula (PCF) is one of the most feared complications after total laryngectomy. A compressive neck dressing is often applied after surgery to try to prevent it, but there is no consensus on whether it works or how long it should be kept, and practice varies widely between centers. This multicenter, retrospective, observational study compares the rate of PCF in adult patients with laryngeal squamous cell carcinoma who underwent primary total laryngectomy with direct closure of the hypopharyngeal mucosa and who did or did not receive a postoperative compressive dressing. It also examines whether the duration of the dressing affects the risk of fistula and how fistulas were managed in the two groups. All data are collected from existing medical records; no additional treatment or examination is performed.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Description détaillée

PCF occurs in about 14% of primary total laryngectomies and about 28% of salvage procedures. It is associated with prolonged hospital stay, higher costs, delayed adjuvant treatment, and further complications. No study has directly compared patients managed with and without a postoperative compressive dressing.

This is a non-profit, multicenter, national, retrospective observational study coordinated by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Consecutive patients who underwent primary total laryngectomy from January 1, 2014 to the study start date are included. All patients were treated according to routine clinical practice at each center. Patients are divided into two groups according to postoperative management: compressive dressing of the cervical region over the neopharyngeal suture (Group A) or no compressive dressing (Group B).

Data are extracted from medical records and entered in pseudonymized form in an electronic case report form (REDCap). Collected variables include demographics, smoking and alcohol use, comorbidities, preoperative laboratory values and inflammatory indices, tumor site and clinical stage, surgical details (neck dissection, thyroidectomy, pharyngeal closure technique, salivary stent, primary voice prosthesis), postoperative antibiotic protocol, time to oral feeding, and fistula characteristics and management.

The planned sample size is 950 patients (475 per group), which provides 80% power to detect a 6.0% difference in fistula rate between groups, assuming a baseline rate of 14.3% in the group without compressive dressing, using a two-sided Fisher's exact test with alpha 0.05. The primary outcome will be analyzed with Fisher's exact test. Secondary outcomes will be analyzed with logistic and linear regression. Confounding will be addressed with propensity score matching, inverse probability weighting, or covariate adjustment, as appropriate.

Type d'étude

Observationnel

Inscription (Estimé)

950

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Bergamo, Italie
        • Recrutement
        • ASST Papa Giovanni XXIII
        • Contact:
          • Giovanni Danesi, Medical Degree
          • Numéro de téléphone: +39 035 2674398
          • E-mail: gdanesi@asst-pg23.it
      • Bologna, Italie
        • Recrutement
        • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
        • Contact:
          • Edoardo Serafini, Medical Degree
          • Numéro de téléphone: +39 051 2145263
      • Bologna, Italie
        • Recrutement
        • Ospedale Maggiore Carlo Alberto Pizzardi
        • Contact:
      • Bolzano, Italie
        • Recrutement
        • Ospedale Centrale di Bolzano
        • Contact:
          • Luca Calabrese, medical degree
          • Numéro de téléphone: +39 0471 438641
          • E-mail: orlbz@sabes.it
      • Brescia, Italie
        • Recrutement
        • ASST degli Spedali Civili di Brescia
        • Contact:
      • Candiolo, Italie
        • Recrutement
        • IRCCS Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia
        • Contact:
      • Cesena, Italie
        • Recrutement
        • Ospedale M. Bufalini
        • Contact:
      • Florence, Italie
        • Recrutement
        • Azienda Ospedaliero-Universitaria Careggi
        • Contact:
          • Giandomenico Maggiore, Medical Degree
          • Numéro de téléphone: +39 055 7942000
      • Forlì, Italie
        • Recrutement
        • Ospedale G.B. Morgagni - L. Pierantoni
        • Contact:
      • Milan, Italie
      • Milan, Italie
      • Modena, Italie
        • Recrutement
        • Azienda Ospedaliero-Universitaria Policlinico di Modena
        • Contact:
      • Naples, Italie
      • Padova, Italie
        • Recrutement
        • Azienda Ospedale-Università di Padova
        • Contact:
      • Pavia, Italie
        • Recrutement
        • Fondazione IRCCS Policlinico San Matteo
        • Contact:
      • Pescara, Italie
      • Ravenna, Italie
      • Reggio Emilia, Italie
        • Recrutement
        • Arcispedale Santa Maria Nuova
        • Contact:
      • Rimini, Italie
      • Roma, Italie
      • Roma, Italie
      • Roma, Italie
      • Torino, Italie
        • Recrutement
        • AOU Città della Salute e della Scienza (Molinette)
        • Contact:
      • Trieste, Italie
        • Recrutement
        • Ospedale di Cattinara
        • Contact:
          • Giancarlo Tirelli, Medical Degree
          • Numéro de téléphone: +39 040 3994933
          • E-mail: tirellig@units.it
      • Verona, Italie
        • Recrutement
        • Azienda Ospedaliera Universitaria Integrata di Verona
        • Contact:
      • Vittorio Veneto, Italie
        • Recrutement
        • Ospedale di Vittorio Veneto - ULSS 2 Marca Trevigiana
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

N/A

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Consecutive adult patients with squamous cell carcinoma of the larynx who underwent primary total laryngectomy with direct closure of the hypopharyngeal mucosa at the participating Italian otolaryngology centers from January 1, 2014 to the study start date.

La description

Inclusion Criteria:

  • Squamous cell carcinoma of the larynx treated with primary total laryngectomy
  • Primary closure of the hypopharyngeal mucosa
  • Age 18 years or older
  • Informed consent to study participation and to personal data processing
  • Availability of data on comorbidities, laboratory parameters, and postoperative management

Exclusion Criteria:

  • Salvage total laryngectomy
  • Previous radiotherapy or chemoradiotherapy to the head and neck
  • Previous open surgery of the pharyngolaryngeal region
  • Reconstruction with a free or pedicled flap (inlay or onlay)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: RETROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Compressive dressing (Group A)

Patients who received a postoperative compressive dressing of the cervical region over the neopharyngeal suture after primary total laryngectomy, according to routine clinical practice at the treating center.

Postoperative compressive dressing applied to the cervical region over the neopharyngeal suture. This is an exposure observed in routine clinical practice; it is not assigned by the study.

No compressive dressing (Group B)

Patients who did not receive a postoperative compressive dressing after primary total laryngectomy, according to routine clinical practice at the treating center.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Incidence of pharyngocutaneous fistula
Délai: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number and percentage of patients who develop a pharyngocutaneous fistula in each group (compressive dressing vs no compressive dressing).

During the postoperative hospital stay (from surgery to discharge), up to 60 days

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Incidence of pharyngocutaneous fistula by duration of compressive dressing
Délai: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number and percentage of patients in Group A who develop a pharyngocutaneous fistula, stratified by duration of the compressive dressing (days).

During the postoperative hospital stay (from surgery to discharge), up to 60 days
Time to onset of pharyngocutaneous fistula
Délai: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number of days from surgery to diagnosis of pharyngocutaneous fistula in each group.

During the postoperative hospital stay (from surgery to discharge), up to 60 days
Type of management of pharyngocutaneous fistula
Délai: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number and percentage of patients with fistula managed conservatively (compressive dressing) or surgically in each group.

During the postoperative hospital stay (from surgery to discharge), up to 60 days
Resolution of pharyngocutaneous fistula
Délai: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number and percentage of patients whose fistula resolved, by initial group and type of management.

During the postoperative hospital stay (from surgery to discharge), up to 60 days
Time to resolution of pharyngocutaneous fistula
Délai: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number of days from diagnosis to resolution of the fistula, by initial group and type of management.

During the postoperative hospital stay (from surgery to discharge), up to 60 days

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Edoardo Serafini, Medical Degree, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

5 mai 2025

Achèvement primaire (Estimé)

5 janvier 2027

Achèvement de l'étude (Estimé)

31 mars 2027

Dates d'inscription aux études

Première soumission

15 novembre 2026

Première soumission répondant aux critères de contrôle qualité

15 novembre 2026

Première publication (Réel)

19 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

19 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

15 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 162/2025/Oss/AOUBo

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

De-identified individual participant data underlying the published results will be made available upon reasonable request to the Principal Investigator.

Délai de partage IPD

After publication of the study results in a peer-reviewed journal.

Critères d'accès au partage IPD

Data will be shared with researchers who submit a motivated request to the Principal Investigator of the coordinating center (IRCCS Azienda Ospedaliero-Universitaria di Bologna).

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .